Eli Lilly's tirzepatide drug significantly reduced type 2 diabetes risk by 94% in obese prediabetic adults over three years, with sustained weight loss.

Eli Lilly's weight loss drug tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, significantly reduced the risk of type 2 diabetes by 94% in adults with prediabetes and obesity or overweight over a three-year period, according to a long-term trial. The study also reported sustained weight loss during the treatment period.